Short Interest in Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Decreases By 82.0%

Posted by Alphonse Anthony on Dec 26th, 2025

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY – Get Free Report) was the recipient of a large decrease in short interest during the month of December. As of December 15th, there was short interest totaling 326 shares, a decrease of 82.0% from the November 30th total of 1,809 shares. Based on an average daily volume of 624,935 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the company’s stock are sold short. Currently, 0.0% of the company’s stock are sold short. Based on an average daily volume of 624,935 shares, the short-interest ratio is presently 0.0 days.

Analysts Set New Price Targets

Separately, Zacks Research lowered shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research report on Wednesday, November 19th. One analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy”.

Get Our Latest Report on Daiichi Sankyo

Daiichi Sankyo Stock Up 1.9%

DSNKY traded up $0.40 on Friday, reaching $21.82. The company’s stock had a trading volume of 97,241 shares, compared to its average volume of 259,398. The stock has a market cap of $41.34 billion and a price-to-earnings ratio of 20.59. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.31 and a quick ratio of 1.60. The business’s 50 day moving average is $23.32 and its 200 day moving average is $23.89. Daiichi Sankyo has a 1 year low of $20.51 and a 1 year high of $29.68.

About Daiichi Sankyo

(Get Free Report)

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody?drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.